Merimepodib
- Generic Name
- Merimepodib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H24N4O6
- CAS Number
- 198821-22-6
- Unique Ingredient Identifier
- 2ZL2BA06FU
- Background
Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.
- Indication
For the treatment of hepatitis C virus (HCV) infection.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- ViralClear Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04410354
- Locations
- 🇺🇸
Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸HCA Houston Healthcare Medical Center, Houston, Texas, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C
- Conditions
- First Posted Date
- 2004-07-28
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 315
- Registration Number
- NCT00088504
- Locations
- 🇺🇸
David N. Schwartz, M.D., Attleboro, Massachusetts, United States
🇺🇸Lawrence D. Wruble, M.D., Memphis, Tennessee, United States
🇺🇸Lawton Shick, M.D., Worcester, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.